{"protocolSection": {"identificationModule": {"nctId": "NCT01498679", "orgStudyIdInfo": {"id": "113719"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.", "officialTitle": "A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily for 12 Weeks in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With Low to Mid-strength Inhaled Corticosteroid or Low-strength Combination Therapy."}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-01"}, "primaryCompletionDateStruct": {"date": "2013-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-12-21", "studyFirstSubmitQcDate": "2011-12-21", "studyFirstPostDateStruct": {"date": "2011-12-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-02-13", "resultsFirstSubmitQcDate": "2014-02-13", "resultsFirstPostDateStruct": {"date": "2014-04-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-01-25", "lastUpdatePostDateStruct": {"date": "2017-03-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A randomised, double-blind, placebo-controlled, parallel group multicentre study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily for 12 weeks in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with lowe to mid-strength inhaled corticosteroid or low-strength combination therapy.", "detailedDescription": "This will be a randomised, double-blind, placebo controlled, parallel group, multi-centre study. At Visit 1 (Screening Visit) subjects who meet all of the inclusion criteria and none of the exclusion criteria will enter a two week run-in period. Subjects will remain on their current ICS therapy throughout the run-in period. At the end of the run-in period (Visit 2) subjects meeting the Randomisation criteria will enter a 12 week treatment period and receive one of the two following treatments: 1) FF/VI (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI) 2) Placebo administered once daily in the evening via a NDPI In addition, all subjects will be supplied with albuterol/salbutamol inhalation aerosol to be used as required to treat asthma symptoms.\n\nSubjects who have not met the randomisation criteria at Visit 2 will be withdrawn from the study.\n\nSubjects meeting the randomisation criteria will be randomized to one of the two treatment groups and will attend the clinic for 3 on-treatment visits at Week 4 (Visit 3), Week 8 (Visit 4) and Week 12 (Visit 5). Subjects will receive treatment for 12 weeks. A Follow-up Visit or phone call (Visit 6) will take place 1 week after completing study medication. All clinic visits will take place in the morning. Subjects will participate in the study for a maximum of 15 weeks (Screening to Follow-up inclusive). A subject is regarded to have completed the study if they complete all phases of the study (Screening, treatment, Follow-up)."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 311, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "fluticasone furoate/vilanterol trifenatate", "type": "ACTIVE_COMPARATOR", "description": "Inhaled corticosteroid (ICS)/Long-acting beta2-agonist (LABA) combination", "interventionNames": ["Drug: GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "placebo comparator", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)", "description": "ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)", "armGroupLabels": ["fluticasone furoate/vilanterol trifenatate"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo administered once daily in the evening via a NDPI", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period", "description": "Peak Expiratory Flow is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 12-week Treatment Period minus the Baseline value. Analysis was performed using Analysis of Covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment.", "timeFrame": "Baseline and Weeks 1-12 (up to Day 84)"}], "secondaryOutcomes": [{"measure": "Mean Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value. A Repeated Measures analysis adjusted for Baseline, region, sex, age, treatment, week, week by Baseline interaction, and week by treatment interaction was used.", "timeFrame": "Baseline and Weeks 1-12 (up to Day 84)"}, {"measure": "Mean Change From Baseline in the Percentage of Rescue-free 24- Hour (hr) Periods During the 12-week Treatment Period", "description": "The number of inhalations of rescue albuterol/salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 12-week Treatment Period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline is calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "timeFrame": "Baseline and Weeks 1-12 (up to Day 84)"}, {"measure": "Mean Change From Baseline in the Percentage of Symptom-free 24- Hour (hr) Periods During the 12-week Treatment Period", "description": "Asthma symptoms were recorded in a daily diary by the participants every day in the morning and evening before taking any rescue or study medication and before PEF measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered as symptom free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Participants who were symptom free for 24-hour periods during the 12-week Treatment Period were assessed. Change from Baseline is calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "timeFrame": "Baseline and Weeks 1-12 (up to Day 84)"}, {"measure": "Change From Baseline in Total Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire developed to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The 32 items of the questionnaire are averaged to produce one overall quality of life score. The response format consists of a 7-point scale, where a value of 1 indicates \"total impairment\" and a value of 7 indicates \"no impairment.\" Change from Baseline was calculated as the Week 12 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "timeFrame": "Baseline and Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Informed Consent: All subjects must be able and willing to give written informed consent to take part in the study.\n2. Type of Subject: Outpatients, of Asian ancestry, 12 years of age or older at Visit 1 (or \u226518 years of age or older if local regulations or the regulatory status of study medication permit enrolment of adults only), with a diagnosis of asthma as defined by the Global Initiative for Asthma \\[GINA, 2009\\] at least 12 weeks prior to Visit 1.\n3. Gender: Male or Eligible Female, defined as non-childbearing potential or childbearing potential using a protocol defined acceptable method of birth control consistently and correctly. Female subjects should not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study participation. A serum pregnancy test is required for females of childbearing potential at the initial Screening Visit (Visit 1) and Visit 5 or Early Withdrawal\n4. Severity of Disease: A best FEV1 of 40%-90% of the predicted normal value at the Visit 1, Screening visit. Predicted values will be based upon NHANES III using the adjustment for Asians \\[Hankinson, 2010\\].\n5. Reversibility of Disease: Demonstrated \u226512% and \u2265200mL reversibility of FEV1 within 10-40minutes following 2-4 inhalations of albuterol/salbutamol inhalation aerosol (or one nebulised treatment with albuterol/salbutamol solution) at the Screening Visit.\n6. Current Anti-Asthma Therapy: All subjects must be using an ICS, with or without LABA, for at least 12 weeks prior to Visit 1, in accordance with the protocol defined acceptable dose ranges.\n7. Short-Acting Beta2-Agonists: All subjects must be able to replace their current short-acting beta2-agonists with albuterol/salbutamol inhaler at Visit 1 for use as needed for the duration of the study. Subjects must be able to withhold albuterol/salbutamol for at least 4 hours prior to study visits\n\nExclusion Criteria:\n\n1. History of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 10 years.\n2. Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.\n3. Asthma Exacerbation: Any asthma exacerbation requiring oral corticosteroids within 12 weeks of Visit 1 or that resulted in overnight hospitalization requiring additional treatment for asthma within 6 months prior to Visit 1.\n4. Concurrent Respiratory Disease: A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or other respiratory abnormalities other than asthma.\n5. Other Concurrent Diseases/Abnormalities: A subjects must not have any clinically significant, uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the patient at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study.\n6. Oropharyngeal Examination: A subject will not be eligible for the run-in if he/she has clinical visual evidence of candidiasis at Visit 1.\n7. Allergies: \u2022Drug Allergy: Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the new powder inhaler (i.e., lactose or magnesium stearate). \u2022Milk Protein Allergy: History of severe milk protein allergy.\n8. Concomitant Medications: Use of the protocol defined prohibited medications prior to Screening (Visit 1) or during the study, in accordance with the protocol.\n9. Tobacco Use: Current smoker or subjects with a smoking history of 10 pack years (e.g., 20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products within the past 3 months (i.e., cigarettes, cigars, smokeless or pipe tobacco).\n10. Affiliation with Investigator's Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, Sub Investigator, study coordinator, or employee of the participating Investigator.\n11. Previous Participation: A subject may not have previously been Randomized to treatment in another Phase III fluticasone furoate/VI combination product study (i.e., HZA113714, HZA106827, HZA106829, HZA106837, HZA106839, HZA106851, HZA113091).\n12. Compliance: A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, disease, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol, including visit schedule and completion of the daily diaries.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "100 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Shenzhen", "state": "Guangdong", "zip": "518020", "country": "China", "geoPoint": {"lat": 22.54554, "lon": 114.0683}}, {"facility": "GSK Investigational Site", "city": "Zhanjiang", "state": "Guangdong", "zip": "524001", "country": "China", "geoPoint": {"lat": 21.28145, "lon": 110.34271}}, {"facility": "GSK Investigational Site", "city": "Nanning", "state": "Guangxi", "zip": "530021", "country": "China", "geoPoint": {"lat": 22.81667, "lon": 108.31667}}, {"facility": "GSK Investigational Site", "city": "Haikou", "state": "Hainan", "zip": "570311", "country": "China", "geoPoint": {"lat": 20.04583, "lon": 110.34167}}, {"facility": "GSK Investigational Site", "city": "Shenyang", "state": "Liaoning", "zip": "110015", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "GSK Investigational Site", "city": "Yinchuan", "state": "Ningxia", "zip": "750004", "country": "China", "geoPoint": {"lat": 38.46806, "lon": 106.27306}}, {"facility": "GSK Investigational Site", "city": "Xian", "state": "Shaanxi", "zip": "710032", "country": "China", "geoPoint": {"lat": 34.25833, "lon": 108.92861}}, {"facility": "GSK Investigational Site", "city": "Qingdao", "state": "Shandong", "zip": "266071", "country": "China", "geoPoint": {"lat": 36.06488, "lon": 120.38042}}, {"facility": "GSK Investigational Site", "city": "Hang Zhou", "state": "Zhejiang", "zip": "310003", "country": "China"}, {"facility": "GSK Investigational Site", "city": "Beijing", "zip": "100029", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "GSK Investigational Site", "city": "Beijing", "zip": "100034", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "GSK Investigational Site", "city": "Beijing", "zip": "100050", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "GSK Investigational Site", "city": "Chongqing", "zip": "400037", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "GSK Investigational Site", "city": "Chongqing", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "GSK Investigational Site", "city": "Hangzhou", "zip": "310016", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "GSK Investigational Site", "city": "Shanghai", "zip": "200433", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "GSK Investigational Site", "city": "Bucheon-si, Gyeonggi-Do", "zip": "420-767", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "GSK Investigational Site", "city": "Cheongju, Chungcheongbuk-do", "zip": "361-711", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Ilsanseo-gu, Goyang-si, Gyeonggi-do", "zip": "411706", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Pusan", "zip": "602-739", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "GSK Investigational Site", "city": "Seongnam-si, Gyeonggi-do", "zip": "463-707", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Seoul,", "zip": "120-752", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "110-744", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "130-709", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "137-701", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "152-703", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Marilao, Bulacan", "zip": "3019", "country": "Philippines"}, {"facility": "GSK Investigational Site", "city": "Quezon City", "zip": "1101", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}]}, "referencesModule": {"references": [{"pmid": "27401316", "type": "DERIVED", "citation": "Lin J, Tang H, Chen P, Wang H, Kim MK, Crawford J, Jacques L, Stone S. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist. Allergy Asthma Proc. 2016 Jul;37(4):302-10. doi: 10.2500/aap.2016.37.3968."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "113719", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113719", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113719", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113719", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113719", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113719", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113719", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "At screening, participants who met all of the inclusion criteria entered a 2-week Run-in Period. Participants continued on inhaled corticosteroid (ICS) therapy throughout the Run-in Period. At the end of the Run-in Period, participants meeting the randomization criteria entered a 12-week Treatment Period and received one of the two treatments.", "recruitmentDetails": "A total of 311 participants were randomized to treatment. However, 4 participants were randomized in error and did not receive any study treatment. These participants were not included in the Intent-to-Treat (ITT) Population, which was comprised of all participants randomized to treatment who received \\>=1 dose of trial medication.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening,via a Dry Powder Inhaler (DPI), for a period of 12 weeks."}, {"id": "FG001", "title": "Fluticasone Furoate/Vilanterol 100/25 \u00b5g Once Daily", "description": "Participants received fluticasone furoate (FF)/vilanterol (VI) 100/25 micrograms (\u00b5g) OD in the evening,via a DPI, for a period of 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "154"}, {"groupId": "FG001", "numSubjects": "153"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "65"}, {"groupId": "FG001", "numSubjects": "131"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "89"}, {"groupId": "FG001", "numSubjects": "22"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "72"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received placebo OD in the evening,via a DPI, for a period of 12 weeks."}, {"id": "BG001", "title": "Fluticasone Furoate/Vilanterol 100/25 \u00b5g Once Daily", "description": "Participants received FF/VI 100/25 \u00b5g OD in the evening,via a DPI, for a period of 12 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "154"}, {"groupId": "BG001", "value": "153"}, {"groupId": "BG002", "value": "307"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.4", "spread": "13.90"}, {"groupId": "BG001", "value": "47.0", "spread": "14.01"}, {"groupId": "BG002", "value": "47.2", "spread": "13.94"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "88"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "171"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "66"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "136"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Asian - East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "132"}, {"groupId": "BG001", "value": "125"}, {"groupId": "BG002", "value": "257"}]}]}, {"title": "Asian - South East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "50"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period", "description": "Peak Expiratory Flow is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 12-week Treatment Period minus the Baseline value. Analysis was performed using Analysis of Covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment.", "populationDescription": "Intent-to-Treat (ITT) Population: all participants randomized to treatment who received \\>=1 dose of trial medication. The primary endpoint analysis only included participants who had PM PEF data for \\>=4 days in the BL week prior to randomization and \\>=4 days after randomization. Only participants available at the indicated time point were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters/minute (L/min)", "timeFrame": "Baseline and Weeks 1-12 (up to Day 84)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo OD in the evening,via a DPI, for a period of 12 weeks."}, {"id": "OG001", "title": "Fluticasone Furoate/Vilanterol 100/25 \u00b5g Once Daily", "description": "Participants received FF/VI 100/25 \u00b5g OD in the evening,via a DPI, for a period of 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.8", "spread": "3.16"}, {"groupId": "OG001", "value": "39.2", "spread": "3.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least Squares Mean Difference", "paramValue": "51.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "42.2", "ciUpperLimit": "59.7"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value. A Repeated Measures analysis adjusted for Baseline, region, sex, age, treatment, week, week by Baseline interaction, and week by treatment interaction was used.", "populationDescription": "ITT Population. Only those participants who had AM PEF data for at least 2 days in the Baseline week prior to randomization and at least 2 days after randomization and were available at the indicated time point were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline and Weeks 1-12 (up to Day 84)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo OD in the evening,via a DPI, for a period of 12 weeks."}, {"id": "OG001", "title": "Fluticasone Furoate/Vilanterol 100/25 \u00b5g Once Daily", "description": "Participants received FF/VI 100/25 \u00b5g OD in the evening,via a DPI, for a period of 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.3", "spread": "3.12"}, {"groupId": "OG001", "value": "43.6", "spread": "3.12"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Percentage of Rescue-free 24- Hour (hr) Periods During the 12-week Treatment Period", "description": "The number of inhalations of rescue albuterol/salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 12-week Treatment Period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline is calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of rescue-free 24-hr periods", "timeFrame": "Baseline and Weeks 1-12 (up to Day 84)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo OD in the evening,via a DPI, for a period of 12 weeks."}, {"id": "OG001", "title": "Fluticasone Furoate/Vilanterol 100/25 \u00b5g Once Daily", "description": "Participants received FF/VI 100/25 \u00b5g OD in the evening,via a DPI, for a period of 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.3", "spread": "2.59"}, {"groupId": "OG001", "value": "30.1", "spread": "2.60"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Percentage of Symptom-free 24- Hour (hr) Periods During the 12-week Treatment Period", "description": "Asthma symptoms were recorded in a daily diary by the participants every day in the morning and evening before taking any rescue or study medication and before PEF measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered as symptom free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Participants who were symptom free for 24-hour periods during the 12-week Treatment Period were assessed. Change from Baseline is calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of symptom-free 24-hr periods", "timeFrame": "Baseline and Weeks 1-12 (up to Day 84)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo OD in the evening,via a DPI, for a period of 12 weeks."}, {"id": "OG001", "title": "Fluticasone Furoate/Vilanterol 100/25 \u00b5g Once Daily", "description": "Participants received FF/VI 100/25 \u00b5g OD in the evening,via a DPI, for a period of 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.0", "spread": "2.30"}, {"groupId": "OG001", "value": "24.8", "spread": "2.31"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire developed to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The 32 items of the questionnaire are averaged to produce one overall quality of life score. The response format consists of a 7-point scale, where a value of 1 indicates \"total impairment\" and a value of 7 indicates \"no impairment.\" Change from Baseline was calculated as the Week 12 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "populationDescription": "ITT Population. Only those participants available at the indicated time point were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo OD in the evening,via a DPI, for a period of 12 weeks."}, {"id": "OG001", "title": "Fluticasone Furoate/Vilanterol 100/25 \u00b5g Once Daily", "description": "Participants received FF/VI 100/25 \u00b5g OD in the evening,via a DPI, for a period of 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.33", "spread": "0.094"}, {"groupId": "OG001", "value": "0.84", "spread": "0.068"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the follow up (up to Study Day 91).", "description": "SAEs and non-serious AEs were reported for members of the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received \\>=1 dose of trial medication.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo OD in the evening,via a DPI, for a period of 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 154, "otherNumAffected": 27, "otherNumAtRisk": 154}, {"id": "EG001", "title": "Fluticasone Furoate/Vilanterol 100/25 \u00b5g Once Daily", "description": "Participants received FF/VI 100/25 \u00b5g OD in the evening,via a DPI, for a period of 12 weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 153, "otherNumAffected": 24, "otherNumAtRisk": 153}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}]}, {"term": "Enteritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 153}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 153}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 153}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Clinic visit", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}